Florida Senate - 2013 SENATOR AMENDMENT
Bill No. CS for CS for SB 966
Barcode 931602
LEGISLATIVE ACTION
Senate . House
.
.
.
.
.
—————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————
Senator Bean moved the following:
1 Senate Amendment (with title amendment)
2
3 Delete lines 2420 - 2425
4 and insert:
5 4. Managed care plans must permit an enrollee who was
6 receiving a prescription drug and was on the plan’s formulary
7 and subsequently removed or changed, to continue receiving that
8 drug if the provider submits a written request demonstrating
9 that the drug is medically necessary and that the enrollee meets
10 clinical criteria to receive the drug.
11 5. Managed care plans must establish procedures to ensure
12 that:
13 a. There is a response to a request for prior consultation
14 by telephone or other telecommunication device within 24 hours
15 after receipt of a request for prior consultation.
16 b. A 72-hour supply of the drug prescribed is provided in
17 an emergency or if the managed care plan does not provide a
18 response within 24 hours.
19 c. The prior authorization process for prescribed drugs is
20 readily accessible to health care providers, including posting
21 appropriate contact information on the managed care plan’s
22 website and providing timely responses to providers.
23 d. If a drug, determined to be medically necessary and
24 prescribed for an enrollee by a physician using sound clinical
25 judgment, is subject to prior authorization and approved, a
26 managed care plan provides for sufficient refills to complete
27 the duration of the prescription. If the medication is still
28 clinically appropriate for ongoing therapy after the initial
29 prior authorization expires, the plan must provide a process of
30 expedited review to evaluate ongoing therapy.
31 6. Managed care plans shall implement a step-therapy prior
32 authorization approval process for medications excluded from the
33 preferred drug list. Medications on the preferred drug list must
34 be used within the previous 12 months before using alternative
35 medications that are not listed. The trial period between the
36 specified steps may vary according to the medical indication.
37 The step-therapy approval process shall be developed in
38 accordance with the Medicaid Pharmaceutical and Therapeutics
39 Committee, as provided in s. 409.91195(7) and (8). A drug
40 product may be approved without meeting the step-therapy prior
41 authorization criteria if the prescribing physician provides the
42 managed care plan with additional written medical or clinical
43 documentation that the product is medically necessary because:
44 a. There is no acceptable clinical alternative drug on the
45 preferred drug list to treat the disease or medical condition;
46 b. The alternatives have been ineffective in the treatment
47 of the beneficiary’s disease; or
48 c. Based on historic evidence and known characteristics of
49 the patient and the drug, the drug is likely to be ineffective,
50 or the number of doses have been ineffective.
51
52 Managed care plans shall work with physicians to determine the
53 best alternative for patients. The agency may adopt rules
54 waiving the requirements for written clinical documentation for
55 specific drugs in limited clinical situations.
56
57 ================= T I T L E A M E N D M E N T ================
58 And the title is amended as follows:
59 Delete line 215
60 and insert:
61 plan’s formulary; requiring managed care plans to
62 establish procedures relating to prior authorization
63 review and to ensure that patients receive a
64 sufficient supply of drugs to complete ongoing
65 therapy; providing criteria for the implementation of
66 a step-therapy prior authorization process; requiring
67 managed care plans to work with physicians regarding
68 alternative treatments; providing for the adoption of
69 rules; revising references to certain